What are the most common in vitro drug-drug interaction study gaps?
Certara drug interaction science experts share data and experimental design gaps commonly found in in…
CertaraJune 9, 2025
Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions
Director, Clinical Pharmacology, ORIC Pharmaceuticals SVP, Head of Simcyp PBPK Modeling Services, Certara Director, PBPK…
CertaraApril 21, 2025
Measuring metabolites in index clinical DDI studies
February 7, 2025A key drug development safety consideration is whether the drug candidate will interact…
CertaraFebruary 7, 2025
Optimizing DDI Knowledge throughout Drug Development
Lorem ipsum dolor sit amet consectetur. Donec diam risus volutpat tempor. Massa accumsan aliquam nibh…
CertaraJanuary 6, 2025
Static Versus Dynamic Model Predictions of Competitive Inhibitory Metabolic Drug–Drug Interactions via Cytochromes P450: One Step Forward and Two Steps Backwards
Predicting metabolic drug–drug interactions (DDIs) via cytochrome P450 enzymes (CYP) is essential in drug development,…
CertaraDecember 12, 2024
Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator
The article "Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system…
CertaraAugust 26, 2024
